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1. Introduction 
Gaucher disease (GD) (GD, OMIM 230800), is the most common glycosphingolipid storage 
disorder, with an estimated global prevalence of 1:200,000 of the population (Cox & Schofield, 
1997). Impaired activity of the lysosomal enzyme, ǃ-glucocerebrosidase, leads to build-up of 
glucosylceramide in macrophages, forming dysfunctional, lipid-engorged ‘Gaucher cells’ that 
accumulate primarily in the liver, spleen, bone, lungs and nervous system (Grabowski & 
Horowitz, 1997; Beutler, 1997). Figure 1 Sometimes, bone disease or cellular infiltration in bone 
marrow, could be lead to fractures or hematomas that cause neurological complications from 
compression of the spinal cord or peripheral nervous system. In addition, severe deficiency of 
ǃ-glucocerebrosidase increases the accumulation in the central nervous system of 
glucosylceramide and other toxic metabolites in the neuronopathic involvement. However the 
precise mechanisms by which glucosylceramide storage originate them is still unclear. The 
frequency of neurological GD cases is ranging between 7% and 17%, according to different 
series (Biegstraaten et al., 2008; Chérin et al., 2010). 
 
 
Fig. 1. Biosynthesis and degradation of sphingolipid 
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2. Clinical characteristics of neurological forms 
The neuronopathic forms of GD can be either acute type 2 (GD2) (MIM 230900), or chronic 
type 3 (GD3) (MIM 231000), the presence of neurological symptoms is the main 
characteristics for a diagnosis, nevertheless in a low percentage of type 1 GD (GD1) some 
neurological manifestations could be considered part of the GD1 phenotype.  
These forms are considered as ultrarare and estimated at about 5% for GD3 and 1% for GD2 
(Charrow et al., 2000).  
2.1 Type 2 Gaucher disease 
There are many descriptions of type 2 Gaucher disease presenting with hydrops fetalis and 
joint contractures. In the majority of cases with this severe phenotype, glucocerebrosidase 
activity is absent or severely deficient. In general, most patients with Gaucher disease do 
have some residual glucocerebrosidase activity, with no correlation between severity and 
the level of residual enzyme activity. 
The patients with the acute form, usually die within two years. The initial neurological 
symptoms as paralysis of horizontal gaze supranuclear are followed later, with strabismus, 
impaired vertical gaze, dysarthria, difficulty in swallowing, chewing, laryngeal stridor and a 
pyramidal syndrome with opisthotonos. Some of these patients develop a progressive 
encephalopathy that is neocortical in origin. The molecular and cellular bases for the 
phenotypic variation and the progression of the neuronopathic features in Gaucher disease 
are poorly understood. Few studies are available from human tissues that correlate 
neuronopathic progression, pathologic involvement, and the clinical manifestations. To fill 
this void, several mouse models with GCase null or point mutations or chemical inhibition 
were developed. The GCase-null mutations exhibited a defective skin permeability barrier, 
similar to that in collodion babies. Skin permeability barrier defects lead to death shortly 
after birth and have limited their utility in understanding the pathogenesis in CNS of type 2 
and 3 Gaucher disease (Xu et al, 2008) 
2.2 Type 3 Gaucher disease 
The patients with chronic form, GD3, the first neurological symptoms usually appear at a 
mean age of 8 years, and the patients with myoclonic epilepsy variant by age 15 (Park et al., 
2003) in these cases the life expectancy can reaches the third decade. Nevertheless, there 
have been reported some cases of apraxia of gaze without progression to other neurological 
symptoms (Kraoua et al., 2011).  There are other GD3 subtypes, GD3b, the neurological 
involvement is limited to apraxia of the eyes, but is associated with visceral enlargement 
and bone disease. (Patterson et al., 1993). Other less common GD3 subtype, have been 
classified as 3c characterized by heart valves calcification and eye movement disorders 
(Chabas et al., 1995).  
The GD3 has heterogeneous clinical manifestations, and therefore different subtypes have 
been referred. GD3 subtype a, is characterized by apraxia of gaze and dementia associated 
with myoclonic epilepsy, ataxia and extrapyramidal signs or spasticity. In addition in this 
subtype there are several specific forms including the myoclonus epilepsy as the main 
manifestation (Park et al., 2003). These neurological forms have slight or moderate visceral 
involvement and bone changes are characterized by chest deformities and kyphoscoliosis, 
which may have a neurological basis, however bone crises normally are absent (Tylki-
Szymańska et al., 2010). 
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2.2.1 Myoclonic epilepsy 
Different lysosomal storage diseases: late-onset GM2 gangliosidosis, type 2 GM1 
gangliosidosis, Niemann-Pick disease, sialidosis, galactosialidosis, pseudodeficiencia of 
arylsulfatase A, Gaucher disease and some forms of ceroid lipofuscinosis have been 
associated with myoclonic epilepsy (Tinuper et al., 1994; Kowarz et al., 2005). 
The main form is an association between Gaucher disease and myoclonic epilepsy in a rare 
subgroup of patients with GD type 3 who developed a progressive myoclonus epilepsy. All 
had horizontal saccadic eye movements. The lack of a shared genotype for patients and the 
variability in clinical presentations suggesting the existence of other modifying factors 
contributing to this rare phenotype (Park et al., 2003). Have also been documented cases in 
Spanish population with symptoms of myoclonic epilepsy (Giraldo et al., 2011). In a study 
of a Spanish patient with neuronopathic type 3 GD and myoclonic epilepsy symptomatic 
improvement was observed using a combination of substrate reduction therapy with 
enzyme replacement therapy (Capablo et al., 2007). 
Although the mutation N188S in the GBA gene in Gaucher disease was initially considered 
a mild mutation or a variant modifier has been reported the association of this mutation 
with the development of myoclonic epilepsy, suggesting that the enzyme could lead to 
abnormal death of neuronal cells or modify the role of other proteins involved in epilepsy 
(Kowarz et al., 2005). In recent years, understanding the genetic basis of myoclonic epilepsy 
has progressed rapidly and several defects have been identified, specific genes and 
mutations (Scheffer & Berkovic, 2000, Stafstrom et al., 2000, Delgado-Escueta et al. 2001). 
Recently genes have been identified for other forms of progressive myoclonus epilepsy: 
a. The CLN3 gene has been associated with a type of neuronal ceroid lipofuscinosis, 
Batten disease, contains 15 exons and spans over 15 Kb. The International Batten 
Disease Consortium isolated the gene CLN3 between microsatellite markers D16S288 
and D16S383 on chromosome 16p12.2.1-16p11 (International Batten Disease 
Consortium, 1995). It is speculated that the gene product functions as a chaperone 
involved in folding / unfolding or assembly / disassembly of other proteins, 
specifically the subunit c of ATP synthase complex (Janes et al., 1996). Biochemically 
mutation causes multiple deficiencies in the enzyme complexes of the respiratory chain 
involving NADH-CoQ reductase (complex I) in the cytochrome C oxidase (COX). 
b. A mutation at nucleotide 8344 of human mitochondrial DNA causes MERRF 
(Myoclonus Epilepsy Associated with Ragged-Red Fibers) (Shoffner et al., 1990). 
c. The gene for cystatin B (CSTB) is located on chromosome 21 in a segment of about 
175KB, between D21S2040 and D21S1259. Expands into three exons over 2500bp, 
encoding a small protein of 98 amino acids. Mutations in the gene encoding cystatin B 
are responsible for primary defect in patients with progressive myoclonus epilepsy type 
Unverricht-Lundborg (EPM1) autosomal recessive (Pennacchio et al., 1996). The 
encoded protein is a member of the superfamily of cysteine protease inhibitors 
(Jarvinen & Rinne, 1982, Turk & Bode, 1991). 
d. EPM2A gene is located on chromosome 6q24 and contains 5 exons that encode two 
laforin isoforms, isoform A is located in the rough endoplasmic reticulum and isoform 
B in the nucleus. Laforin is a dual specificity phosphatase and functions are involved in 
protein degradation by the proteasome (Lohi et al., 2005) and glycogen metabolism 
(Worby et al., 2006). Mutations in the gene EPM2A cause deleterious effects on protein 
encoding the laforin, causing Lafora disease, which is an autosomal recessive 
progressive myoclonic epilepsy (Minassian et al., 1998). 
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3. Histological changes in neurological forms 
The neuropathological studies (Wong et al., 2004) in patients with different types of GD 
have found clear pathologic changes in several areas of the brain, mainly in the form of 
perivascular Gaucher cells, astrogliosis and neuronal loss. Immunohistochemical findings in 
the same study suggest that, in certain areas, elevated intracellular levels of 
glucocerebroside would further reduce glucocerebrosidase levels and contribute to citoxicity 
as well as to abnormalities in calcium homeostasis and increased sensitivity of neurons, thus 
facilitating spontaneous neuronal discharges. More recent data reinforces the role of 
citotoxic molecules, but possibly related to the intraneuronal accumulation of the defective 
enzyme (Futerman; 2006). It has also been proposed that the accumulation of 
glucosylsphingosine, is responsible for the neurological symptoms (Pelled et al., 2005). On 
the other hand, the finding that mutation N188S may be associated with the development of 
myoclonic epilepsy, suggests that the abnormal enzyme might lead to neuronal cell death, 
or modify the role on other proteins involved in epilepsy (Kowarz et al., 2005). 
Neuropathological exam in a GD3 patient suggests that cerebellum-dentate degeneration 
would play a major role in these patients’ myoclonus (Verghese et al., 2000). How this 
relates to in vivo cortical dysfunction is unclear. Probably, other factors in addition to point 
mutations, environmental, epigenetic and genetic, will ultimately be involved in the 
development of myoclonic epilepsy in GD patients.  
In some cases of myoclonic epilepsy an improvement in neurological symptoms have been 
observed with substrate reduction therapy (SRT), the biochemical basis of this improvement 
could be related with small molecules that have been shown to enter the CNS both in animal 
models and in patients and this was an important argument maybe related to the reduction 
of glucocerebroside accumulation by the substrate reduction activity. It could also be related 
to the described chaperoning effect on the defective glucocerebrosidase or a functional 
improvement, through a yet unknown mechanism, in the defective calcium homeostasis 
described above (Pelled et al., 2005).  
4. Clinical characteristics of type 1 Gaucher Disease 
Classically, GD1 is characterized by organomegaly, cytopenias, bone disease and absence of 
neurological manifestations. However, there are several reports of the co-occurrence of 
neurological problems, as a consequence of spinal cord or nerve compression following 
vertebral body collapse or bleeding within confined compartments (Grewel et al., 1991). 
There is accumulating evidence that in a few GD patients, prominent neurological 
abnormalities may become evident during adult life (McKeran et al., 1985). Several new 
lines of evidence have implicated an association between GD and the development of 
parkinsonism. The first hints of a relationship between the two disorders were suggested by 
scattered case reports of patients with Gaucher disease who developed early-onset, 
treatment-refractory parkinsonism (Neudorfer et al., 1996; Machaczka et al., 1999; Tayebi et 
al., 2001). In a clinic-based series of Parkinson disease patients from Israel, (Aharon-Peretz et 
al., 2004) screened for the most frequent mutations in glucocerebrosidase gene, they 
identified 31% with glucocerebrosidase mutations including three N370S homozygotes. This 
frequency was at least fivefold higher than the observed in their two control groups used. 
In an international collaborative study conducted in sixteen countries with 5961 patients 
with Parkinson disease in all ethnic groups, compared with 4898 controls, the odds ratio 
estimated for any type of GBA mutation has been of 5.43 (Sidransky et al., 2009).  
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We have studied the characteristics of Gaucher disease in Iberian Peninsula. The Iberian 
Peninsula (IP) is located in the extreme Southwest of Europe and includes the states of 
Portugal and Spain. It is the second-largest peninsula in Europe, with an area of 580,000 
square kilometers and with a total 55 million of inhabitants. The actual IP genetic pool has 
been influenced by many major populations and immigrations, including the Paleolithic 
Iberian population, which already existed by 50,000 B.C. Later, by North Africans who 
entered the Iberian region between 20,000 and 8,000 B.C. and by the Saharans, who arrived 
between 8,000 and 4,000 B.C. In addition, there were also people coming from central 
Europe (also generically called Celt invasions), during the first millennium B.C. At the 
beginning of the 8th century Islamic peoples (generically called Arabs) entered Spain 
(Arnaiz Villena et al 1999, Côrte-Real HB et al 1996). Taking into account all these data, 
nowadays it is believed that, the timing of divergence of populations within Iberia points to 
a shared ancestry of all populations in the Upper Palaeolithic. Further genetic subdivision is 
apparent in Catalonia and Andalusia, with increased genetic diversity in the latter. Lineage 
diversity comparisons of IP populations with European (Tuscan) and North African 
(Algerian) populations shows the Iberian Peninsula to be more similar to other European 
populations, although a small number of Iberian lineages can be traced to North Africa. 
Since the early 70s, the group of Dr. Chabas in Barcelona (Spain) and the Dr. Sa Miranda in 
Porto (Portugal) has been dedicated to the identification and study of lysosomal storage 
diseases including GD (Cormand et al. 1995, 1998; Amaral et al 1993). Moreover since 1993, 
the Spanish Foundation for the Study and Treatment of Gaucher Disease (FEETEG) keeps 
the Spanish Registry of GD (SRGD) and also coordinates the screening, diagnosis, 
characterization, treatment, and follow-up of GD patients in Spain (Giraldo et al. 2000, 
Alfonso et al 2007). 
Of the 436 subjects included in this series, the 96.1% were born in Iberian Peninsula, Balearic 
and Canary Islands,  92 patient were from Portugal (21.1%) and 327 (75.0%) Spanish origin 
and 17 were immigrants (3.9%),   Patients born at IP were classified at diagnosis: 370 as GD 
type 1 (88.3%) (age mean: 40.6 ± 20.30 years, range 0.3–87); 28 as GD type 2 (6.7%) (Age: 
mean 0.4 years, range 0–1) and 21 as GD type 3 (5.0%) (Age: mean 5.9 years, range 2–17). 
Mean age at diagnosis in the total GD patients was 26.3±19.88 years (range 0-87) and 28.7 
years in patients type 1.  To date, 63 patients from IP in this series are death (15%) and 373 
are alive (85%). According the type distribution 7.6% of type 1; 52.4% of type 3 and 100% of 
type 2 are death. 
4.1 Association of Parkinsonism with Gaucher disease 
Parkinson disease (PD), the second most common neurodegenerative disorder after 
Alzheimer's disease, has a complex and multifactorial etiology, with different contributions: 
genetic, epigenetic and environmental. It can be classified by age of onset as early PD or late 
PD and in the form of presentation as family or sporadic PD. 
The main clinical phenotype of Parkinson's disease is characterized by motor dysfunction 
such as bradykinesia, tremor at rest, rigidity and postural instability, but can also affect 
autonomic functions and knowledge (Poewe, 2008). 
The prevalence of the disease is associated with age, and is approximately 1 in 100 
individuals at 65 years and increasing to 4-5% at the age of 85 years (Van den Eeden et al., 
2003). 
Parkinson's disease is mainly due to a progressive degeneration of dopaminergic neurons in 
the substantia nigra and other monoaminergic cell groups of the brain (Braak et al., 2003), 
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resulting in increased microglial activation and accumulation of proteins in the surviving 
dopaminergic neurons, known as Lewy bodies and Lewy neurites (Forno, 1996). Symptoms 
appear when between 50-70% of nigrostriatal dopaminergic neurons are lost. 
Although Parkinson's disease has been considered a genetic disorder of not sporadic origin, 
only 5 to 10% of patients show monogenic forms of the disease. Some genes are associated 
with Parkinson's disease, and several of them are presented in an autosomal dominant or 
autosomal recessive.  
Autosomal dominant: PARK1/ǂ-sinucleín, PARK4/ǂ-sinucleín, PARK8/Leucine-rich 
repeat kinase 2 (LRRK2) and microtubule associated protein tau (MAPT). 
Autosomal recessive: The PARK2 gene is located on chromosome 6q25.2-q27 and comprises 
12 exons with intron structure superexpanded of 1.3 Mb of genomic DNA, which encodes a 
protein of 465 amino acid N-terminal domain similar to ubiquitin. Mutations in the parkin 
gene (PARK2) were identified for the first time in several Japanese families with autosomal 
recessive juvenile parkinsonism (Kitada et al., 1998). 
PTEN-induced PARK6/Quinasa 1 (PINK1). Homozygous mutations in this gene were 
found originally in patients with early-onset Parkinson's, and account for between 1 to 2% of 
cases of early onset of Parkinson's disease (Hatano et al., 2004). 
The PINK1 gene, located on 1p35-36, contains 8 exons spread over 1.8 kb and encodes a 
protein of 581 amino acids. The transcript is expressed ubiquitously and encodes a protein 
kinase domain of a highly conserved, which is also in the family of Ca2 + / calmodulin 
serine-threonine kinases (Valente et al., 2004). 
DJ1 PARK7/Oncogen, DJ1 gene, located on chromosome region 1p36, contains 8 exons that 
span 24 Kb and is located 25 cM from the telomere of the PINK1 gene (Bonifati et al., 2003). 
Deletions have been identified and mutations that cause amino acid change <1% of early-
onset parkinsonism (Lockhart et al., 2004). 
Monogenic forms represent less than 10% of Parkinson disease in most populations and are 
the result of complex interactions between genes and environmental factors. Genetic 
variations could be susceptibility factors or disease modifiers, affecting the penetrance, age 
of onset, severity and progression. 
The results of different studies show an association between Gaucher and Parkinson's 
disease by the occurrence of Gaucher disease and atypical parkinsonism in patients, 
appearing between the fourth and sixth decades of life, and the identification of mutations 
in the gene the GBA in probands with sporadic Parkinson's disease. 
There are different hypotheses about how to explain the association of Parkinson disease 
and Gaucher Disease. One of them claims that glucocerebrosidase gene (GBA) mutations can 
produce an aberrant protein with function gain either hetero or homozygous and facilitate 
the alpha-synuclein aggregation this effect could induces neuronal toxicity.  Wild-type 
alpha-synuclein could be selectively translocated into lysosomes for degradation by the 
chaperone-mediated autophagy pathway (Cuervo et al., 2004).  
Under these conditions the receptor LAMP2 would saturate their transport capacity, 
resulting in a jam intracellular alpha-synuclein. Another scenario would involve directly the 
accumulation of misfolded mutated glucocerebrosidase protein in the endoplasmic 
reticulum leading to a situation of stress, and decreased activity of parkin, an ubiquitin 
ligase associated with the occurrence of early onset of Parkinson disease. This stress could 
trigger the start of the mechanisms of neuronal apoptosis in the substantia nigra, and 
therefore the onset of disease (Ron et al., 2010).  
Moreover, only in patients with the two GBA mutant alleles the functional deficit of 
glucocerebrosidase, may cause accumulation of glucocerebroside and glucoesphyngosine 
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that interfere with the determination of alpha-synuclein to lipid membranes, facilitating the 
aggregation of alpha-synuclein and the formation of Lewy bodies (Schlossmacher et al., 
2005). 
4.2 Other neurological manifestations in type 1 Gaucher Disease 
Pastores et al conducted an epidemiological survey in order to ascertain the incidence of 
neurological symptoms in patients with GD1 (Pastores et al., 2003). This survey revealed 
that a significant proportion of patients with GD I experience neurological symptoms. In 
addition, we found that GD1 patients have a greater risk of suffering other common 
unrelated diseases than carriers or their healthy relatives (Giraldo et al., 2011). 
The wide spectrum phenotypic variation and neurological involvement within all types, and 
the recognition of an increasing number of subgroups of patients, support the view that GD 
is a disorder with a phenotypic continuum ranging from prenatal lethality to asymptomatic 
adults (Sidransky, 2004). Figure 2 
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Fig. 2. Phenotype continuum in Gaucher disease 
A recent systematic review of published literature identified 86 studies in which patients 
with GD1, or carriers of a glucocerebrosidase gene mutation, had some form of neurological 
manifestation (Biegstraaten et al., 2008; Cherin et al., 2010) contrary to the classical 
neuronopathic phenotypical description. Peripheral nervous system manifestations appear 
to be of particular relevance in GD1. An epidemiological survey of GD1 patients undergoing 
long-term enzyme replacement therapy (ERT) revealed that 73% of patients had at least one 
neurological symptom, including paraesthesia, tremor, muscular weakness, muscle cramps 
and sciatica, most of which were thought to be due to peripheral nervous system disease 
(Pastores et al., 2003). A case–control survey in 107 GD1 patients (untreated or receiving 
ERT) corroborated these findings, reporting a significantly higher frequency of symptoms 
related to peripheral neuropathy (Halperin et al., 2007). However, the above studies were 
limited by the absence of a neurological examination and standardised nerve conduction 
studies, and as yet there are no reliable estimates of the prevalence of peripheral neuropathy 
in GD1 (Biegstraaten et al., 2010), the vast majority of these cases have subclinical peripheral 
neuropathy only detected by electroneurophysiological exams. Figure 3 
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Fig. 3. Sensorial nerve conduction in type 1 Gaucher Disease patient. Abnormal wave forms 
in radial nerve. 
The aetiology of polyneuropathy related to GD1 has not yet been elucidated, although 
certain associated conditions may predispose patients to develop neurological disease. 
Relevant conditions might include monoclonal gammopathies, vitamin B12 deficiency and 
diabetes mellitus (Gielchinsky et al., 2001; de Frost et al., 2008; Silverman et al., 2008). The 
pathophysiology of nerve injury in GD remains speculative, but may be related to an 
imbalance in calcium homeostasis. Elevated intraneuronal glucocerebroside concentrations 
have been shown to induce a 300% increase in calcium-induced calcium release by 
influencing the RyaR channel, which has been proposed as one of the mechanisms 
responsible for neuronal injury in the central nervous system of neuronopathic GD (Lloyd-
Evans et al., 2003). Whether this mechanism plays a role in peripheral nerve injury is 
unknown, but increased intracellular calcium has been implicated in the pathophysiology of 
diabetic neuropathy and neuropathic pain (Hall et al., 2001; Yaksh,2006; Finnerup et al., 
2007). 
In conclusion, polyneuropathy and other peripheral nerve involvement appear to be part of 
the natural course of disease in patients with GD1, highlighting the need for increased 
vigilance for peripheral neurological abnormalities 
5. Mutations in GBA and neuronopatic forms of Gaucher Disease   
The gene for human GCase, GBA, consists of 11 exon, have 7.2–7.4 kb in size, and maps to 
chromosome 1q21 (Barneveld et al., 1983). A pseudogene that shares 96% exonic sequence 
homology with GBA is located at 16 kb downstream from the functional gene (Horowitz et 
al., 1989). Figure 4. The pseudogene is transcribed, but does not produce a functional protein 
(Sorge et al., 1990). A significant number of mutations are present in the GBA pseudogene, 
and there are mutant alleles caused by gene conversion events with the pseudogene named 
recombinant alleles, Rec or pseudogene like mutations. Over 300 mutations have been 
identified worldwide in GBA and over 50 different mutations have been described in 
patients with neuronopatic involvement (Hruska et al., 2008) and also see 
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http://www.hgmd.org. They represent a spectrum of non-sense, missense and splice mutations 
as well as gene rearrangements. Most of these mutations are rare or private mutations, but 
two missense mutations, N370S and L444P, have significant frequencies in the majority of 
populations. It has been suggested that the genotype plays an important role in determining 
the degree of neurological involvement; however genotype-phenotype correlations are not 
straightforward in GD (Beutler & Grabowski., 2001; Koprivica et al., 2000). The most 
consistent finding is that the presence of the N370S mutation, either in homozygosity or in 
heterozygosity, always precludes development of neurological manifestation (Grabowski, 
1997).  
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Fig. 4. Structure of glucocerebrosidase gene GBA and Seudogene Ψ-GBA 
However,  L444 P homozygosity has been shown to be associated with a neuronopathic 
phenotype in various populations, including   Spanish, Swedish, Pole, Ashkenazi Jewish, 
and other Caucasian populations, while it was clearly associated with non-neuronopathic 
Gaucher disease in Taiwanese–Chinese (Wan et al., 2006; Goker-Alpan et al., 2005; Koprivica 
et al., 2000; Stone, 2000). These observations strongly suggest that other factors, such as 
modifier loci, promoter mutations, environmental factors, and other non-genetic causes, 
must play roles in the observed genotype-phenotype variability and also that modifying 
genes could be associated with the ethnic-related genetic diversity (Montfort et al., 2004; 
Alfonso et al., 2010).  
To try to identify relationships genotype-phenotype, two approaches may be useful. First, 
the use of homogenous populations would tend to diminish genetic variation, as a 
consequence, the observed phenotype can be attributed to the identified mutants with 
greater assurance.  However, this approach is limited by the need of large sample size to 
identify sufficient numbers of homozygotes for study, and to guarantee the homogeneity.  
The second approach is to study patients with most severe disease, and the least amount of 
residual activity. It is assumed that both mutant alleles have to be highly disruptive in these 
cases. 
An additional problem arises from the analysis method used; most laboratories relied solely 
on Polymerase Chain Reaction (PCR) based mutation-detection techniques to screen for the 
presence or absence of specific mutations. PCR amplification of a specific fragment has 
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inherent problems, because a complex allele with more than one mutation, a mutation 
located at a primer site or a deleted allele could not be detected and therefore the published 
studies on genotype-phenotype relationship may be biased. Moreover, recombinant alleles 
would not be identified because using this approach alleles carrying a portion of the 
pseudogene sequence will not be amplified by primers designed to be specific for the 
glucocerebrosidase gene, and the patient may mistakenly be designated as a homozygote for 
the second allele (Torralba et al., 2002; Tayebi et al.,1999) 
Given these limitations, we note that some generalizations were observed that suggested 
genotype–phenotype correlations: 1) homozygosis for the L444P mutation is usually, if not 
always, associated with neuronopatic forms 2). L444P is the most common mutation 
identified in patients with the intermediate phenotype. 3) the combination of one allele with 
L444P mutation and another mutation with a null or very severe allele seemed to be 
associated with the most severe neurological form, type 2. 4) perinatal lethality due to 
hydrops fetalis often resulted from homozygosis for a null or a recombinant allele. 5) None 
of the patients with type 2 are carriers of  the N370S mutation, commonly found  in GD1. 
It is important to point out that there is an overlap between the GD2 and GD3 phenotypes 
making it difficult to categorize, on the other hand, the differentiation between GD1 and 
GD3 is sometimes difficult during early adulthood and the patients may have to be re-
classified if neurological deficits, appear later in life. Therefore it is possible that Gaucher 
disease, classically divided into three types have a continuum of phenotypes.  
There are a large number of genotypes associated with neuronopatic forms of GD. In 
Western countries, an association can be drawn between the presence of the N370S allele in 
combination with other mutation and GD1. Conversely, the L444P allele is most frequently 
associated to the neuronopathic variants.  Data from 47 neurological cases included in the 
Spanish Gaucher Disease Registry, SGDR, (Alfonso et al., 2007; Giraldo et al., 2000) indicate 
that the most frequent allele is L444P accounting for 38.3% of the total alleles, followed by 
D409H 18.1% and the double mutant allele [E326K; L444P] 12.8%. Table 1.  
Seventeen per cent of the total neurological GD cases included in the SGDR were 
homozygous for L444P mutation. It is interesting to note that this genotype was found in 
two patients classified as GD2 and in 6 GD3 and the homozygous for [E326K; L444P] as 
GD2. Surprisingly one patient with myoclonic epilepsy was carrier of N370S mutation, 
genotype N370S/G195W, no other mutations were identified in this patient in spite that the 
entire GBA was sequenced and analysed large rearrangements. It is important to point out 
that we do not know if in this case the cause of neurological impairment was due to the GBA 
gene or to other gene, gene-gene interaction or gene-environment interaction and  therefore 
we dared not classify them as GD2 or GD3.  
As we mentioned before the N370S mutation has been traditionally associated with the 
absence of neurological disease; however, several studies reported a high proportion of 
patients with the N370S mutation were diagnosed with GD 1 and showed  mild 
neurological symptoms  such  tremor, peripheral neuropathy, uncoordinated movements, 
and hearing loss (as well as Parkinson disease. (Capablo et al., 2008; Giraldo et al., 2011; 
Pastores et al., 2003). These findings are consistent with the recently established contention 
that the mutation could not fully protect the patient from the appearance of neurological 
symptoms (Halperin et al., 2007). These observations reinforce the hypothesis that 
phenotypes reflect the continuum of the GD (Sidransky  et al., 2004).  
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 Genotype   Type2 Type3        Percent         
L444P/L444P 2 6 17.0      
D409H/D409H  6 12.8        
[E326K;L444P]/R463H 3  6.3        
G195E/L444P 3  6.3        
c.1263_1317del55/L444P 3  6.3        
D409H/R120W 2  4.2        
D409H/L444P  2 4.2 
[E326K;L444P]/[E326K;L444P] 2  4.2 
[N188S;E326K]/L444P  2 4.2 
R120W/L444P 2  4.2            
[E326K;L444P]/D409H  1 2.1    
[E326K;L444P]/P182L  1 2.1 
[E326K;L444P]/G202R 1  2.1        
[E326K;L444P]/W312R 1  2.1 
[E326K;L444P]/L444P 1  2.1      
G202R/L444P 1  2.1 
I270P/L444P 1  2.1        
RecNciI/L444P 1  2.1        
S364R/L444P 1  2.1        
c.203_204insC/L444P 1  2.1 
G377S/G195W  1 2.1        
R463C/G377S  1 2.1 
N392I/L444P 1  2.1        
V15M/G195W 1  2.1           
Total 27 20 100 
Table 1. GBA genotype distribution in 47 neuronopatic forms of GD from Spanish Gaucher 
Disease Registry 
In a recent study, aimed to determine the presence of neurological symptoms and 
Parkinson’s disease in Spanish GD patients and their relatives, we have found that relatives 
with PD exhibited a wide spectrum of GBA mutations L444P, N370S, V398I, R257Q, G202R, 
c.1439- 1445del7, [E326K; N188S], and c.953delT in the other hand PD was more frequent in 
carriers of L444P mutation and other rare GBA mutations than carriers of N370S (Giraldo et 
al., 2011). 
6. Treatment of neurological forms of Gaucher Disease 
The standard care for GD patients is the enzymatic replacement therapy (ERT), 
unfortunately neurological manifestations of GD are not corrected by ERT. This failure 
should be attributed to the blood–brain barrier which is largely impermeable to proteins.  It 
is noteworthy that children without neurological symptoms at diagnosis that receive early 
infusions of ERT, are bound to develop neurological symptoms in type 3 of disease. 
The other therapy approach used in glycosphingolipid disease, is the inhibition of the 
enzyme glusylceramide synthase and is called substrate reduction therapy (SRT), these 
inhibitors decrease the biosynthesis of the substrate (glucosylceramide). The only licensed 
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SRT is a small iminosugar molecule (Miglustat) that penetrates the blood–brain barrier. In 
spite of the trial conducted in children with chronic neuronopathic GD form, Miglustat do 
not meet its clinical end points and the drug currently is not recommended for neurological 
manifestations in GD. Nevertheless, there are some reports with specific neurological cases 
treated with miglustat that showed improvement in neurological manifestations (Capablo et 
al. 2007). It is interesting that miglustat used by compassionate therapy, in some type3 
Gaucher disease gets to slow the progression of neurological manifestations, in similar 
manner that occurs in the licensed therapy with Miglustat in Niemann–Pick disease type C, 
another lysosomal disease that affects the brain in which there is disturbed cholesterol 
trafficking to lysosomes and causes secondary accumulation of glycosphingolipids in 
neurons (Wraith et al. 2010). 
Bone marrow hematopoietic stem-cell transplantation, is not in current general use for GD, 
partly because of the difficulty to found ideal donors and procedural risks. The introduction 
of successful ERT has superseded this treatment in many countries. Only neurological forms 
in early stages could be rescued by this procedure.  
The gene therapy is an interesting future option. The use of lentivirus-transduced 
autologous hematopoietic stem cells has been applied in other neurodegenerative disease as 
adrenoleukodystrophy (Cartier et al 2009) and currently in clinical trials for metachromatic 
leukodystrophy. Gene therapy has the advantage of being one procedure that requires less 
powerful myeloablative conditioning and thus is applicable for patients predicted to be at 
risk of severe neurological disease (Cox 2010).  
7. Conclusions 
Gaucher Disease is divided classically in three types based on the presence and rate of 
progression of the neurologic manifestations: type 1 non-neuronopathic, type 2 acute 
neuronopathic , and type 3 subacute neuronopathic. However there is an overlap between 
the different types suggesting that the disease have a continuum of phenotypes. There is 
accumulating evidence that in some Gaucher Disease patients classified as type 1, will 
develop neurological abnormalities during adult life such as peripheral neuropathy or early 
onset Parkinson Disease. 
In spite of that, there are some glucocerebrosidase gene mutations associated more 
frequently to neurological forms, nevertheless genotype-phenotype correlations are not 
straightforward in Gaucher Disease. 
The origin of neurological changes has not been clearly established, the neuropathological 
studies have demonstrated damage in several areas of the brain with perivascular Gaucher 
cells, astrogliosis and neuronal loss that could be attributed to intracellular deposits of 
glucocerebroside, and to abnormalities in calcium homeostasis. 
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